$3.90
(Market cap
$298,789 Mln
Recently Viewed
Clear AllMarket cap
$298,789 Mln
Revenue (TTM)
$65,011 Mln
P/E Ratio
16.6
P/B Ratio
5.7
Div. Yield
2.7 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$18,254 Mln
ROE
0.4 %
ROCE
19.4 %
Industry P/E
--
EV/EBITDA
11.8
Debt to Equity
1
Book Value
$21.1
EPS
$7.3
Face value
--
Shares outstanding
2,472,392,003
CFO
$117,929.00 Mln
EBITDA
$115,983.00 Mln
Net Profit
$75,684.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Merck & Company Inc (MRK)
| 17.0 | 6.4 | 13.4 | 51.7 | 3.1 | 11.1 | 8.8 |
|
BSE Sensex*
| -9.5 | -2.9 | -9.0 | 3.2 | 8.6 | 9.0 | 12.0 |
|
S&P 100
| -4.4 | -0.1 | -4.7 | 35.3 | 20.7 | 12.2 | 13.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Merck & Company Inc (MRK)
| 5.8 | -8.7 | -1.7 | 44.8 | 1.9 | -7.1 | 22.4 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Merck & Company Inc (MRK)
|
123.2 | 298,788.6 | 65,011.0 | 18,254.0 | 33.9 | 36.9 | 16.6 | 5.7 |
| 211.6 | 369,388.3 | 61,160.0 | 4,226.0 | 15.4 | 15367.3 | 88.5 | 50.5 | |
| 349.8 | 184,668.4 | 36,741.0 | 7,711.0 | 36.8 | 106.1 | 24.1 | 21.7 | |
| 59.2 | 121,687.4 | 48,194.0 | 7,053.0 | 22.2 | 40.5 | 17.2 | 6.6 | |
| 953.3 | 829,736.1 | 65,179.0 | 20,638.3 | 40.5 | 101.3 | 40.4 | 31.5 | |
| 141.5 | 173,929.9 | 29,443.0 | 8,510.0 | 28.8 | 40.6 | 20.7 | 7.6 | |
| 241.3 | 580,713.4 | 94,193.0 | 26,804.0 | 34.6 | 35 | 21.8 | 7.2 | |
| 154.4 | 295,018.4 | 54,811.3 | 14,055.6 | 31.2 | 31.2 | 21.4 | 6.4 | |
| 27.5 | 158,307.0 | 62,579.0 | 7,770.0 | 16.3 | 8.9 | 20.5 | 1.9 | |
| 47.1 | 116,631.8 | 46,716.0 | 7,813.0 | 20.3 | 10.5 | 20.6 | 1.4 |
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23,... Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey. Address: 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 Read more
Chairman, President & CEO
Mr. Robert M. Davis J.D.
Chairman, President & CEO
Mr. Robert M. Davis J.D.
Headquarters
Rahway, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Merck & Company Inc (MRK) is $123.18 (NYSE) as of 08-Apr-2026 16:02 EDT. Merck & Company Inc (MRK) has given a return of 3.12% in the last 3 years.
The P/E ratio of Merck & Company Inc (MRK) is 16.60 times as on 07-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
14.35
|
4.98
|
|
2024
|
14.77
|
5.46
|
|
2023
|
762.89
|
7.41
|
|
2022
|
19.47
|
6.15
|
|
2021
|
14.89
|
5.08
|
The 52-week high and low of Merck & Company Inc (MRK) are Rs 125.14 and Rs 73.31 as of 09-Apr-2026.
Merck & Company Inc (MRK) has a market capitalisation of $ 298,789 Mln as on 07-Apr-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Merck & Company Inc (MRK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.